DCK Antibody

中文名稱(chēng)：

DCK兔多克隆抗體
貨號(hào)：

CSB-PA283493
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human tonsil tissue using CSB-PA283493(DCK Antibody) at dilution 1/20, on the right is treated with fusion protein. (Original magnification: ×200)

Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Mouse heart tissue, Primary antibody: CSB-PA283493(DCK Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
引用文獻(xiàn)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P27707
基因名：

DCK
別名：

dCK antibody; DCK protein antibody; DCK_HUMAN antibody; Deoxycytidine kinase antibody; Deoxynucleoside kinase antibody; EC 2.7.1 antibody; EC 2.7.1.74 antibody; MGC117410 antibody; MGC138632 antibody; OTTHUMP00000219118 antibody; OTTHUMP00000219119 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human DCK
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:2000
WB	1:200-1:1000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

引用文獻(xiàn)

Hyperthermia improves gemcitabine sensitivity of pancreatic cancer cells by suppressing the EFNA4/β-catenin axis and activating dCK Q He,/,2024

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Phosphorylates the deoxyribonucleosides deoxycytidine, deoxyguanosine and deoxyadenosine. Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents.
基因功能參考文獻(xiàn)：
1. study suggests that DCK knockdown facilitates apoptosis while inhibiting proliferation and tumorigenicity in vivo of cervical cancer HeLa cells. PMID: 28820179
2. Phosphorylated and activated DCK can inhibit radiation-induced cell death including apoptosis and mitotic catastrophe, and promote radiation-induced autophagy through PI3K/Akt/mTOR pathway. PMID: 27879648
3. Low deoxycytidine kinase expression is associated with periampullary adenocarcinoma. PMID: 26362587
4. expression and A9846G AA genotype significantly associated with reduced mortality in pancreatic ductal adenocarcinoma PMID: 26962792
5. recently described a human deoxycytidine kinase mutant (G12) that sensitizes cancer cell lines to treatment with gemcitabine. Here, starting from the G12 variant, we identified a mutant that triggers even greater sensitisation to gemcitabine than G12. PMID: 26485161
6. RNA expression of deoxycytidine kinase (DCK), human equilibrative nucleoside transporter-1 (ENT1) and ribonucleotide reductase M1 (RRM1) were significantly higher and cytidine deaminase (CDA) was significantly lower in ex vivo Ara-C sensitive samples. PMID: 26083014
7. n the multivariate Cox regression analysis, we found that age at diagnosis, wild-type genotype of the CDA A79C polymorphism, and wild-type genotype of the dCK C360G polymorphism were the most significant prognostic factors for predicting the risk of death PMID: 26090398
8. results strongly suggest that (1) the E197K alteration in DCK causes inactivation of DCK, and that (2) loss of the normal E197 allele is the crucial mechanism in acquisition of gemcitabine resistance in the RMKN28 tumor cell line PMID: 26196746
9. DCK rs12648166 and DCK rs4694362 SNPs were associated with hematologic toxicity (OR = 2.63, CI 95% = 1.37-5.04, P = 0.0036 and OR = 2.53, CI 95% = 1.34-4.80, P = 0.0044, respectively). PMID: 25557962
10. These findings indicate that the decitabine metabolic pathway affects its therapeutic effects, lower hENT1 expression may induce primary resistance and down-regulated DCK expression may be related to secondary resistance. PMID: 25533931
11. induction after hypoxia plays a role in the progression of pulmonary fibrosis by contributing to alveolar epithelial cell proliferation PMID: 25358054
12. DCK expression levels are prognostic and had predictive value for sensitivity to 5-FU in pancreatic cancer. PMID: 24618665
13. DCK could regulate the migration and invasion of fibroblast-like synoviocytes through AKT pathway in rheumatoid arthritis patients. PMID: 24294360
14. PP2A constitutively dephosphorylates dCK in cells and negatively regulates its activity. PMID: 24462681
15. Report genetic variation in deoxycytidine kinase and subsequent gemcitabine metabolism. PMID: 23230131
16. It is evident that the DCK and CDA polymorphisms might be the important markers for the AML patients' therapy outcomes in a Chinese population. PMID: 22884143
17. Hematologic toxicity such as neutropenia, thrombocytopenia, and anemia were not associated with three tagged single-nucleotide polymorphisms of deoxycytidine kinase or haplotypes. Genetic variations did not affect survival of the patients. PMID: 23035362
18. High levels of dCK in pancreatic ductal adenocarcinoma predict longer survival times in patients treated with adjuvant gemcitabine. PMID: 22705007
19. These results indicate that the inactivation of DCK is one of the crucial mechanisms in acquisition of gemcitabine resistance. PMID: 22490663
20. Although dFdU increased the net intracellular radioactivity of [5-(3)H]dFdC at 24 h in control cells, this increase was abolished in the absence of dCK activity. PMID: 21832002
21. Data show that the CDA/DCK ratio was 3 fold higher in non-responders than responders (P<.05), suggesting that this could be a mechanism of primary resistance. PMID: 21858090
22. dCK expression level in fludarabine-sensitive patients was much higher than in Flud-resistant patients. PMID: 20137114
23. High deoxycytidine kinase is associated with response to pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer. PMID: 21336182
24. Data show that dCK must make the transition between the open and closed states during the catalytic cycle. PMID: 21351740
25. Overexpressed dCK and knocked down p8 is associated with enhancement of gemcitabine sensitivity in pancreatic cancer. PMID: 21225236
26. Data indicate that variant C28624T showed a lower risk of lymphopenia (P=0.04), but a higher risk of neutropenia. PMID: 21030078
27. We show that ABCG2 influence on clofarabine cytotoxicity was markedly influenced by dCK activity PMID: 21245102
28. Data show that dCK-360G allele was found to increase the risk of mucositis after exposure to low-dose cytarabine in childhood ALL therapy. PMID: 20890066
29. Site-directed mutagenesis demonstrated that only Ser-74 phosphorylation was involved in dCK activation by casein kinase 1 delta, strengthening the key role of this residue in the control of dCK activity. PMID: 20637175
30. Data show that phosphorylation of the three other sites, located in the N-terminal extremity of the protein, does not significantly modify dCK activity, but phosphorylation of Thr-3 could promote dCK stability. PMID: 20544527
31. Data show that methylation was detected in one of the SP1 binding sites of the dCK promoter, in most tested cancer cell lines and in patient samples from brain tumors and leukemia. Methylation might therefore regulate transcription of dCK. PMID: 20544528
32. it is residue Asp133 of dCK that is most responsible for discriminating against the thymine base PMID: 20614893
33. Sensitivity of two pancreatic cancer cell lines transduced with deoxycytidine kinase to gemcitabine elevated dramatically in comparison with control cells. PMID: 20043109
34. alternatively spliced dCK forms found in acute myeloid leukemia cells play an important role in cytarabine resistance PMID: 11830489
35. Molecular basis of 2',3'-dideoxycytidine-induced drug resistance in human cells. PMID: 11952160
36. Data show that inorganic tripolyphosphate (PPP(i)) is a good donor for human ceoxycytidine kinase and deoxyguanosine kinase. PMID: 12535661
37. human deoxycytidine kinase promoter activity is regulated by USF and Sp1 PMID: 14514691
38. dCK can act as a phosphorylase, similar to the nucleoside phosphorylase family of enzymes PMID: 15561147
39. analysis of antitumor drug binding to deoxycytidine kinase PMID: 15571255
40. dCK expression varies between individual samples and between different types of malignancies and may play a role in resistance to ara-C in particular tumor types PMID: 15571257
41. deoxycytidine kinase activity is stimulated by 2-chlorodeoxyadenosine and aphidicolin in the cellular context PMID: 15571258
42. deoxycytidine kinase activity is regulated by reversible phosphorylation PMID: 15571259
43. an increased expression of mRNA, specific for thymidine kinase 1, dCK and thymidine phosphorylase, may be involved in carcinogenic processes in the human thyroid PMID: 15978330
44. dCK activity can be controlled by phosphorylation in intact cells, and Ser-74 is required for activity PMID: 16361699
45. Crystal structures of a deoxycytidine kinase variant lacking a flexible insert (residues 65-79) reveal major changes in the donor base binding loop (residues 240-247) between UDP-bound and ADP-bound forms, involving significant main-chain rearrangement. PMID: 16401075
46. an increase in activity of dCK, TK1 and 2 might be involved in an adaptive response of cultured human squamous lung carcinoma cells to radiation by facilitation of DNA repair PMID: 16969512
47. deoxycytidine kinase has a role in lymphoma cell sensitivity to cladribine PMID: 17065053
48. analysis of phosphorylation sites on human deoxycytidine kinase PMID: 17065079
49. analysis of deoxycytidine kinase reversible phosphorylation in normal human lymphocytes PMID: 17065080
50. deoxycytidine kinase activity is enhanced after pulsed low dose rate and single dose gamma irradiation PMID: 17065085
顯示更多

收起更多
亞細(xì)胞定位：

Nucleus.
蛋白家族：

DCK/DGK family
數(shù)據(jù)庫(kù)鏈接：

HGNC: 2704

OMIM: 125450

KEGG: hsa:1633

STRING: 9606.ENSP00000286648

UniGene: Hs.709

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human